Mussel bionic multifunctional adhesive hydrogel film and preparation method thereof
By using PCA hydrogel film prepared by esterification of polyvinyl alcohol with 3,4-dihydroxycinnamic acid in tissue adhesives, the problems of slow degradation, toxic side effects and insufficient adhesion in the prior art are solved. It realizes stable connection and self-healing on tissue wounds, has anti-infection and antioxidant properties, and is suitable for a variety of clinical applications.
Patent Information
- Application Number
- CN202410911838.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-09
- Publication Date
- 2024-11-22
AI Technical Summary
Existing tissue adhesives have slow degradation, toxic side effects, weak adhesion, inability to be used independently of sutures and staples, and have safety hazards in dynamic tissue contact.
PCA solution is prepared by esterification reaction using enol polymers (such as polyvinyl alcohol) and 3,4-dihydroxycinnamic acid. After dialysis, concentration and lyophilization, it forms an adhesion hydrogel film with a microporous structure. , combining hydrogen bonds, intermolecular interactions and electrostatic forces, has toughness and self-healing ability.
It has achieved rapid construction of stable connections on the surface of tissue wounds, adapted to tissue activities, has anti-infection performance and broad-spectrum antioxidant activity, and promoted wound healing. It is suitable for defects in different shapes, and has long-term stable adherence to tissue wounds, reducing scar and infection risks.
Smart Images

Figure CN118987324A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of adhesive hydrogels, and in particular to a mussel bionic multifunctional adhesive hydrogel film and a preparation method thereof. Background Art
[0002] Suturing is currently the preferred method for closing wounds in clinical practice. However, wound suturing takes a long time during surgery, and removing sutures can cause secondary tissue damage, which can easily lead to risks such as scar hyperplasia, contracture, and infection. The invention of tissue adhesives has brought great technological progress to surgical operations.
[0003] As a new type of medical material, tissue adhesives have made great contributions to simplifying surgical operations, shortening surgical procedures, and promoting postoperative healing. Currently, tissue adhesives used in clinical practice include α-cyanoacrylate (CA) and fibrin glue. Cyanoacrylate adhesives have strong adhesion properties, but they have disadvantages such as slow degradation and toxic side effects. Fibrin adhesives have good bio-tissue compatibility, but due to their weak adhesion, they are applied to some tissue areas with small local stress, so their application range is limited. In addition, these clinical tissue adhesives often cannot be used independently of sutures and staples, and there are safety issues in applications in contact with dynamic tissues. In view of the high clinical demand and the limitations of existing products, it is imperative to develop tissue adhesives with strong adhesion, biodegradability, and commercialization. Summary of the invention
[0004] The present invention aims to provide a mussel bionic multifunctional adhesive hydrogel film and a preparation method thereof, so as to solve the problems of existing tissue adhesives such as slow degradation, toxic side effects, weak adhesion, inability to be used independently of sutures and staples, and potential safety hazards in applications in contact with dynamic tissues.
[0005] In order to achieve the above object, the present invention provides the following method:
[0006] Specifically, it relates to a mussel bionic multifunctional adhesive hydrogel film and a preparation method thereof, which is characterized by:
[0007] The enol polymer is dissolved in DMSO at high temperature, and then a catalyst is added, and after the temperature is lowered, 3,4-dihydroxycinnamic acid is added to react to obtain a PCA solution;
[0008] The PCA solution is dialyzed to remove excess monomers and toxic organic solvents, concentrated by a suspension evaporator, and then freeze-dried to obtain a dry PCA polymer;
[0009] The dried PCA polymer is dissolved in deionized water, and divided into silica gel molds for freeze-drying to obtain a PCA tissue adhesive film.
[0010] In an optional embodiment, the vinyl polymer is polyvinyl alcohol.
[0011] In an optional embodiment, the high temperature condition is 90-100°C.
[0012] In an alternative embodiment, the catalyst is sodium bisulfate.
[0013] Preferably, the preparation step of the PCA solution comprises: dissolving the polymer polyvinyl alcohol in DMSO under high temperature conditions, then adding a catalyst sodium bisulfate, and adding 3,4-dihydroxycinnamic acid to react after the temperature drops to 80-85° C. to obtain the PCA solution.
[0014] In an optional embodiment, the polymer polyvinyl alcohol is dissolved in DMSO at high temperature, and then a catalyst sodium bisulfate is added, and after the temperature is reduced to 80°C, 3,4-dihydroxycinnamic acid is added to react to obtain a PCA solution in a reaction environment of reacting for 22-24 hours under N2 protection.
[0015] Preferably, the usage ratio of the polyvinyl alcohol to the 3,4-dihydroxycinnamic acid is 80-85 mmol:10-15 mmol.
[0016] In an optional embodiment, the steps of dialyzing the PCA solution to remove excess monomers and toxic organic solvents, and concentrating the PCA solution by means of a suspension evaporator include: dialyzing the PCA solution to remove excess monomers and toxic organic solvents, and then concentrating the PCA solution by means of a suspension evaporator until the volume ratio of the PCA solution before and after concentration is 12:1-15:1.
[0017] In an optional embodiment, the step of freeze-drying the PCA solution after the concentration process to obtain a dry PCA polymer is as follows: freeze-drying the PCA solution after the dialysis and concentration process using a freeze dryer for 1-2 days until the solution is in a relatively homogeneous white freeze-dried block to obtain the dry PCA polymer.
[0018] In an optional embodiment, the step of dissolving the dried PCA polymer in deionized water, packaging in silicone molds and freeze-drying to obtain a PCA tissue adhesive film comprises: dissolving the dried PCA polymer in deionized water at a concentration of 80-100 ml, packaging in silicone molds and freeze-drying for 1-2 days to obtain a PCA tissue adhesive film.
[0019] The present invention has the following beneficial effects: In this study, polyvinyl alcohol (PVA) is used as the polymer backbone, and 3,4-dihydroxyphenylacrylic acid (CA) is introduced therein, and a tissue adhesive film with good wet bonding performance is prepared through an esterification reaction. Based on hydrogen bonds, intermolecular interactions and electrostatic forces, the film with a microporous structure can adhere to the wet tissue surface and quickly form a stable connection with the tissue. It has toughness and self-healing ability and can adapt to reciprocating tissue activities. At the same time, the catechol group has a certain antioxidant property, which can remove ROS at the damaged site and promote tissue healing. The mussel-like membrane constructed in this study The tissue adhesive film can quickly build a stable adhesive connection on the surface of the tissue wound, seal and protect the wound tissue, and also has anti-infection properties, which is expected to effectively promote the healing of traumatic wounds. It has super strong adhesive properties and can adhere to the tissue wound for a long time in the presence of tissue fluid and blood; it has good self-healing properties and toughness, and can adapt to reciprocating tissue activities without falling off; it is easy to operate and suitable for defects of different shapes; it has high efficiency and broad-spectrum antioxidant activity. The tissue adhesive film of the present invention can bond and seal tissue wounds, protect the wound surface and exert anti-inflammatory effects, promote tissue healing, and has broad clinical application prospects and significance. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] In order to more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the following is a brief introduction to the drawings required for the specific embodiments or the description of the prior art. In all the drawings, similar elements or parts are generally identified by similar reference numerals. In the drawings, the elements or parts are not necessarily drawn according to the actual scale.
[0021] Figure 1 Schematic diagram of a dry PCA polymer (A) and a PCA tissue adhesive film (B) provided in an embodiment of the present invention.
[0022] Figure 2 1. The scanning electron microscope image (A) and the UV-visible spectrum image (B) of the PCA tissue adhesive film provided by the embodiment of the present invention are shown.
[0023] Figure 3 The figures are the bonding effect diagrams of the PCA tissue adhesive film provided by the embodiments of the present invention at different interfaces (A: glass; B: plastic sealing; C: steel; D: polytetrafluoroethylene; E: rubber).
[0024] Figure 4 This is a diagram showing the bonding effect of the PCA tissue adhesive film provided by an embodiment of the present invention on a moist rat tissue surface.
[0025] Figure 5 This is a schematic diagram of the bone bonding ability of the PCA tissue bonding film provided by an embodiment of the present invention:
[0026] (A) Schematic diagram of bone fragment bonding and shearing
[0027] (B) Shear strength of bone fragments after 3, 6, and 12 hours of PCA film application
[0028] (C) Shear stress-distance curves of bone slices after PCA film application for 3, 6, and 12 hours
[0029] (D) Schematic diagram of bone block bonding and stretching
[0030] (E) Bone block bonding tensile strength after 3, 6, and 12 hours of PCA film application
[0031] (F) Tensile stress-distance curves of bone blocks bonded with PCA film for 3, 6, and 12 hours.
[0032] Figure 6 It is a schematic diagram of the scavenging rate of DPPH total free radicals by PCA tissue adhesive films of different concentrations provided in an embodiment of the present invention. DETAILED DESCRIPTION
[0033] In order to make the technical personnel in the technical field better understand the scheme of the present invention, the technical scheme in the embodiment of the present invention will be clearly and completely described below in combination with the drawings in the embodiment of the present invention. Obviously, the described embodiment is only a part of the embodiment of the present invention, not all the embodiments. Based on the embodiment of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0034] The terms "first", "second", etc. in the specification and claims of the present invention and the above-mentioned drawings are used to distinguish different objects rather than to describe a specific order. In addition, the terms "including" and "having" and any variations thereof are intended to cover non-exclusive inclusions. For example, a process, method, device, product or end including a series of steps or units is not limited to the listed steps or units, but may optionally include steps or units that are not listed, or may optionally include other steps or units inherent to these processes, methods, products or ends.
[0035] Reference to "embodiments" herein means that a particular feature, structure, or characteristic described in conjunction with the embodiments may be included in at least one embodiment of the present invention. The appearance of the phrase in various places in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those skilled in the art that the embodiments described herein may be combined with other embodiments.
[0036] As a new type of medical material, tissue adhesives have made great contributions to simplifying surgical operations, shortening surgical procedures, and promoting postoperative healing. Currently, tissue adhesives used in clinical practice include α-cyanoacrylate (CA) and fibrin glue. Cyanoacrylate adhesives have strong adhesion properties, but they have disadvantages such as slow degradation and toxic side effects. Fibrin adhesives have good bio-tissue compatibility, but due to their weak adhesion, they are applied to some tissue areas with small local stress, so their application range is limited. In addition, these clinical tissue adhesives often cannot be used independently of sutures and staples, and there are safety issues in applications in contact with dynamic tissues. In view of the high clinical demand and the limitations of existing products, it is imperative to develop tissue adhesives with strong adhesion, biodegradability, and commercialization.
[0037] The present invention aims to provide a mussel bionic multifunctional adhesive hydrogel film and a preparation method thereof, so as to solve the problems of existing tissue adhesives such as slow degradation, toxic side effects, weak adhesion, inability to be used independently of sutures and staples, and potential safety hazards in applications in contact with dynamic tissues.
[0038] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0039] This embodiment provides a mussel biomimetic multifunctional adhesive hydrogel film and a preparation method thereof, such as Figure 1 As shown, it is characterized by:
[0040] The enol polymer is dissolved in DMSO at high temperature, and then a catalyst is added, and after the temperature is lowered, 3,4-dihydroxycinnamic acid is added to react to obtain a PCA solution;
[0041] The PCA solution is dialyzed to remove excess monomers and toxic organic solvents, concentrated by a suspension evaporator, and then freeze-dried to obtain a dry PCA polymer;
[0042] The dried PCA polymer is dissolved in deionized water, and divided into silica gel molds for freeze-drying to obtain a PCA tissue adhesive film.
[0043] In an optional embodiment, the vinyl polymer is polyvinyl alcohol.
[0044] In an optional embodiment, the high temperature condition is 90-100°C.
[0045] In an alternative embodiment, the catalyst is sodium bisulfate.
[0046] Preferably, the preparation step of the PCA solution comprises: dissolving the polymer polyvinyl alcohol in DMSO under high temperature conditions, then adding a catalyst sodium bisulfate, and adding 3,4-dihydroxycinnamic acid to react after the temperature drops to 80-85° C. to obtain the PCA solution.
[0047] In an optional embodiment, the polymer polyvinyl alcohol is dissolved in DMSO at high temperature, and then a catalyst sodium bisulfate is added, and after the temperature drops to 80-85°C, 3,4-dihydroxycinnamic acid is added to react to obtain a PCA solution in a reaction environment of reacting for 22-24 hours under N2 protection.
[0048] Preferably, the usage ratio of the polyvinyl alcohol to the 3,4-dihydroxycinnamic acid is 80-85 mmol:10-15 mmol.
[0049] In an optional embodiment, the steps of dialyzing the PCA solution to remove excess monomers and toxic organic solvents, and concentrating the PCA solution by means of a suspension evaporator include: dialyzing the PCA solution to remove excess monomers and toxic organic solvents, and then concentrating the PCA solution by means of a suspension evaporator until the volume ratio of the PCA solution before and after concentration is 12:1-15:1.
[0050] In an optional embodiment, the step of freeze-drying the PCA solution after the concentration process to obtain a dry PCA polymer is as follows: freeze-drying the PCA solution after the dialysis and concentration process using a freeze dryer for 1-2 days until the solution is in a relatively homogeneous white freeze-dried block to obtain the dry PCA polymer.
[0051] In an optional embodiment, the step of dissolving the dried PCA polymer in deionized water, packaging in silicone molds and freeze-drying to obtain a PCA tissue adhesive film comprises: dissolving the dried PCA polymer in deionized water at a concentration of 80-100 ml, packaging in silicone molds and freeze-drying for 1-2 days to obtain a PCA tissue adhesive film.
[0052] like Figure 2 As shown, A is a scanning electron microscope image of the PCA tissue adhesive film. It can be seen that the surface of the film has a microscopic porous structure, which is beneficial for the film to absorb the hydration layer on the tissue surface and is beneficial for bonding. The caffeic acid absorption peak at 280nm in the UV-visible spectrum in B confirms the coupling of CA and PVA chains.
[0053] like Figure 3 and Figure 4 As shown, PCA tissue adhesive film can have good bonding effect on various interfaces and wet rat tissue surfaces;
[0054] like Figure 5As shown in the figure, the bonding performance of PCA tissue adhesive film was further explored by using the shear and tensile bonding experiments of bovine bone slices. The hydrated PCA tissue adhesive film (concentration of 200 mg / mL) had good bonding strength when applied to the surface of bovine bone slices for 3h, 6h, and 12h, respectively. This indicates that the PCA tissue adhesive film can be firmly bonded to the surface of bone tissue, and will not fail due to exposure of the film to the air during long-term use.
[0055] like Figure 6 As shown in the figure, the scavenging rate of DPPH total free radicals by PCA tissue adhesive films of different concentrations increased with the increase of concentration. In summary, PCA tissue adhesive films have good free radical scavenging ability in vitro, which lays a foundation for in vivo applications such as clearing excessive reactive oxygen species at the wound, maintaining redox homeostasis, and preventing oxidative stress-induced tissue damage.
[0056] Example 1
[0057] The enol polymer is dissolved in DMSO at high temperature, and then a catalyst is added, and after the temperature is lowered, 3,4-dihydroxycinnamic acid is added to react to obtain a PCA solution;
[0058] The PCA solution is dialyzed to remove excess monomers and toxic organic solvents, concentrated by a suspension evaporator, and then freeze-dried to obtain a dry PCA polymer;
[0059] The dried PCA polymer is dissolved in deionized water, and divided into silica gel molds for freeze-drying to obtain a PCA tissue adhesive film.
[0060] In an optional embodiment, the vinyl polymer is polyvinyl alcohol.
[0061] In an optional embodiment, the high temperature condition is 90°C.
[0062] In an alternative embodiment, the catalyst is sodium bisulfate.
[0063] Preferably, the preparation step of the PCA solution comprises: dissolving the polymer polyvinyl alcohol in DMSO under high temperature conditions, then adding a catalyst sodium bisulfate, and adding 3,4-dihydroxycinnamic acid to react after the temperature drops to 80° C. to obtain the PCA solution.
[0064] In an optional embodiment, the polymer polyvinyl alcohol is dissolved in DMSO at high temperature, and then a catalyst sodium bisulfate is added, and after the temperature is reduced to 80°C, 3,4-dihydroxycinnamic acid is added to react to obtain a PCA solution in a reaction environment of reacting for 22-24 hours under N2 protection.
[0065] Preferably, the usage ratio of the polyvinyl alcohol to the 3,4-dihydroxycinnamic acid is 85 mmol:10 mmol.
[0066] In an optional embodiment, the steps of dialyzing the PCA solution to remove excess monomers and toxic organic solvents, and concentrating the PCA solution using a suspension evaporator include: dialyzing the PCA solution to remove excess monomers and toxic organic solvents, and then concentrating the PCA solution using a suspension evaporator until the volume ratio of the PCA solution before and after concentration is 12:1.
[0067] In an optional embodiment, the step of freeze-drying the PCA solution after the concentration process to obtain a dry PCA polymer is as follows: freeze-drying the PCA solution after the dialysis and concentration process using a freeze dryer for 1-2 days until the solution is in a relatively homogeneous white freeze-dried block to obtain the dry PCA polymer.
[0068] In an optional embodiment, the step of dissolving the dried PCA polymer in deionized water, packaging in silicone molds and freeze-drying to obtain a PCA tissue adhesive film comprises: dissolving the dried PCA polymer in deionized water at a concentration of 80 ml, packaging in silicone molds and freeze-drying for 1-2 days to obtain a PCA tissue adhesive film.
[0069] Example 2
[0070] The enol polymer is dissolved in DMSO at high temperature, and then a catalyst is added, and after the temperature is lowered, 3,4-dihydroxycinnamic acid is added to react to obtain a PCA solution;
[0071] The PCA solution is dialyzed to remove excess monomers and toxic organic solvents, concentrated by a suspension evaporator, and then freeze-dried to obtain a dry PCA polymer;
[0072] The dried PCA polymer is dissolved in deionized water, and divided into silica gel molds for freeze-drying to obtain a PCA tissue adhesive film.
[0073] In an optional embodiment, the vinyl polymer is polyvinyl alcohol.
[0074] In an optional embodiment, the high temperature condition is 100°C.
[0075] In an alternative embodiment, the catalyst is sodium bisulfate.
[0076] Preferably, the preparation step of the PCA solution comprises: dissolving the polymer polyvinyl alcohol in DMSO under high temperature conditions, then adding a catalyst sodium bisulfate, and adding 3,4-dihydroxycinnamic acid to react after the temperature drops to 80° C. to obtain the PCA solution.
[0077] In an optional embodiment, the polymer polyvinyl alcohol is dissolved in DMSO at high temperature, and then a catalyst sodium bisulfate is added, and after the temperature is reduced to 80°C, 3,4-dihydroxycinnamic acid is added to react to obtain a PCA solution in a reaction environment of reacting for 22-24 hours under N2 protection.
[0078] Preferably, the usage ratio of the polyvinyl alcohol to the 3,4-dihydroxycinnamic acid is 80 mmol:15 mmol.
[0079] In an optional embodiment, the steps of dialyzing the PCA solution to remove excess monomers and toxic organic solvents, and concentrating the PCA solution using a suspension evaporator include: dialyzing the PCA solution to remove excess monomers and toxic organic solvents, and then concentrating the PCA solution using a suspension evaporator until the volume ratio of the PCA solution before and after concentration is 15:1.
[0080] In an optional embodiment, the step of freeze-drying the PCA solution after the concentration process to obtain a dry PCA polymer is as follows: freeze-drying the PCA solution after the dialysis and concentration process using a freeze dryer for 1-2 days until the solution is in a relatively homogeneous white freeze-dried block to obtain the dry PCA polymer.
[0081] In an optional embodiment, the step of dissolving the dried PCA polymer in deionized water, packaging in silicone molds and freeze-drying to obtain a PCA tissue adhesion film comprises: dissolving the dried PCA polymer in deionized water at a concentration of 100 ml, packaging in silicone molds and freeze-drying for 1-2 days to obtain a PCA tissue adhesion film.
[0082] Example 3
[0083] The enol polymer is dissolved in DMSO at high temperature, and then a catalyst is added, and after the temperature is lowered, 3,4-dihydroxycinnamic acid is added to react to obtain a PCA solution;
[0084] The PCA solution is dialyzed to remove excess monomers and toxic organic solvents, concentrated by a suspension evaporator, and then freeze-dried to obtain a dry PCA polymer;
[0085] The dried PCA polymer is dissolved in deionized water, and divided into silica gel molds for freeze-drying to obtain a PCA tissue adhesive film.
[0086] In an optional embodiment, the vinyl polymer is polyvinyl alcohol.
[0087] In an optional embodiment, the high temperature condition is 95°C.
[0088] In an alternative embodiment, the catalyst is sodium bisulfate.
[0089] Preferably, the preparation step of the PCA solution comprises: dissolving the polymer polyvinyl alcohol in DMSO under high temperature conditions, then adding a catalyst sodium bisulfate, and adding 3,4-dihydroxycinnamic acid to react after the temperature drops to 85° C. to obtain the PCA solution.
[0090] In an optional embodiment, the polymer polyvinyl alcohol is dissolved in DMSO at high temperature, and then a catalyst sodium bisulfate is added, and after the temperature is reduced to 85°C, 3,4-dihydroxycinnamic acid is added to react to obtain a PCA solution in a reaction environment of reacting for 22-24 hours under N2 protection.
[0091] Preferably, the usage ratio of the polyvinyl alcohol to the 3,4-dihydroxycinnamic acid is 85 mmol:15 mmol.
[0092] In an optional embodiment, the steps of dialyzing the PCA solution to remove excess monomers and toxic organic solvents, and concentrating the PCA solution using a suspension evaporator include: dialyzing the PCA solution to remove excess monomers and toxic organic solvents, and then concentrating the PCA solution using a suspension evaporator until the volume ratio of the PCA solution before and after concentration is 14:1.
[0093] In an optional embodiment, the step of freeze-drying the PCA solution after the concentration process to obtain a dry PCA polymer is as follows: freeze-drying the PCA solution after the dialysis and concentration process using a freeze dryer for 1-2 days until the solution is in a relatively homogeneous white freeze-dried block to obtain the dry PCA polymer.
[0094] In an optional embodiment, the step of dissolving the dried PCA polymer in deionized water, packaging in silicone molds and freeze-drying to obtain a PCA tissue adhesion film comprises: dissolving the dried PCA polymer in deionized water at a concentration of 90 ml, packaging in silicone molds and freeze-drying for 1-2 days to obtain a PCA tissue adhesion film.
[0095] The above is only an embodiment of the present invention, and the common knowledge such as the known specific technical solutions or characteristics in the solution is not described in detail here. It should be pointed out that for those skilled in the art, without departing from the solution of the present invention, several modifications and improvements can be made, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the present invention and the practicality of the patent. The scope of protection required by this application shall be based on the content of its claims, and the specific implementation methods and other records in the specification can be used to interpret the content of the claims.
Claims
1. A mussel bionic multifunctional adhesive hydrogel film and a preparation method thereof, characterized in that: The method comprises: The enol polymer is dissolved in DMSO at high temperature, and then a catalyst is added, and after the temperature is lowered, 3,4-dihydroxycinnamic acid is added to react to obtain a PCA solution; The PCA solution is dialyzed to remove excess monomers and toxic organic solvents, concentrated by a suspension evaporator, and then freeze-dried to obtain a dry PCA polymer; The dried PCA polymer is dissolved in deionized water, and divided into silica gel molds for freeze-drying to obtain a PCA tissue adhesive film.
2. The mussel bionic multifunctional adhesive hydrogel film and preparation method thereof according to claim 1, characterized in that: The vinyl alcohol polymer is polyvinyl alcohol.
3. The mussel bionic multifunctional adhesive hydrogel film and preparation method thereof according to claim 1, characterized in that: The high temperature condition is 90-100°C.
4. The mussel bionic multifunctional adhesive hydrogel film and preparation method thereof according to claim 1, characterized in that: The catalyst is sodium bisulfate.
5. The mussel bionic multifunctional adhesive hydrogel film and preparation method thereof according to claim 1, characterized in that: The preparation steps of the PCA solution include: The polymer polyvinyl alcohol is dissolved in DMSO under high temperature conditions, and then a catalyst sodium bisulfate is added, and after the temperature is lowered to 80-85° C., 3,4-dihydroxycinnamic acid is added for reaction to obtain the PCA solution.
6. According to claim 5, a mussel biomimetic multifunctional adhesive hydrogel film and a preparation method thereof, the step of preparing the PCA solution further comprises: The polymer polyvinyl alcohol is dissolved in DMSO under high temperature conditions, and then a catalyst sodium bisulfate is added. After the temperature is reduced to 80-85°C, 3,4-dihydroxycinnamic acid is added to react to obtain a PCA solution in a reaction environment of 22-24 hours under N2 protection.
7. The mussel biomimetic multifunctional adhesive hydrogel film and the preparation method thereof according to claim 6, characterized in that: The usage ratio of the polyvinyl alcohol and the 3,4-dihydroxycinnamic acid is 80-85 mmol:10-15 mmol.
8. The mussel biomimetic multifunctional adhesive hydrogel film and preparation method thereof according to claim 1, characterized in that: The step of dialyzing the PCA solution to remove excess monomers and toxic organic solvents and concentrating the solution by a suspension evaporator comprises: The PCA solution is dialyzed to remove excess monomers and toxic organic solvents, and then concentrated using a suspension evaporator until the volume ratio of the PCA solution before and after concentration is 12:1-15:
1.
9. The mussel bionic multifunctional adhesive hydrogel film and preparation method thereof according to claim 1, characterized in that: The step of freeze-drying the PCA solution after the concentration process to obtain a dry PCA polymer is: The PCA solution after the dialysis and concentration process is freeze-dried using a freeze dryer for 1-2 days until the solution becomes a relatively homogeneous white freeze-dried block to obtain the dry PCA polymer.
10. The mussel bionic multifunctional adhesive hydrogel film and the preparation method thereof according to claim 9, characterized in that: The step of dissolving the dried PCA polymer in deionized water, packaging in silica gel molds for freeze-drying, and obtaining a PCA tissue adhesive film comprises: The dried PCA polymer is dissolved in deionized water at a concentration of 80-100 ml, and divided into silica gel molds for freeze drying for 1-2 days to obtain a PCA tissue adhesive film.
